JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China (NMPA) has accepted the supplemental Biological License Application (sBLA) for Carteyva® (relmacabtagene autoleucel injection). The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva® by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.